The Medicines Control Agency (M.C.A.) warns all medicine importers, wholesalers, retailers, dispensers, and prescribers to desist from using medicine products from Maiden Pharmaceuticals of India.
The M.C.A. warning in a press release issued on 30th November says anyone found wanting for the sale and distribution of medicine products from Maiden Pharmaceuticals will be prosecuted under the Medicines Act of 2014.
“The M.C.A. wishes to strictly warn importers, wholesalers, retailers, dispensers, and prescribers against using all products manufactured by Maiden Pharmaceuticals Limited of 81 H.S.I.D.C. Industrial Area of Kundli 131028, D.I.S.T.T., Sonepat, (Haryana), India.
“Maiden Pharmaceuticals Limited is blacklisted by M.C.A., and all its products are banned by M.C.A. for use in The Gambia since 2022.
“In light of the above, you are strictly warned to desist from the distribution and sale of all Maiden Pharmaceuticals Limited products such as syrups, tablets, capsules, injections, etc.”
The warning comes on the heels of the ongoing court case at the high court in Banjul, after parents of around 70 Gambian children who died last year from Acute Kidney Injury filed a suit after reportedly consuming syrups imported from Maiden Pharmaceuticals in India.
Henceforth, the agency will tighten surveillance and market controls to prevent the distribution and sale of Maiden Pharmaceuticals products in the country.
It wants the public to report any suspected trading of products manufactured by Maiden Pharmaceuticals in The Gambia.
